Triple negative breast cancer
Triple negative breast cancer accounts for around 15% of breast cancers. It is usually more aggressive, harder to treat, and more likely to recur than many other cancers.
CLX001 is a peptide in a nanoparticle formulation, developed for the treatment of triple negative breast cancer, with potential for expansion into ovarian cancer and other solid tumour cancers. It is designed for precision destruction of cancer cells using a novel mechanism of action which targets the tumour environment without requiring specific cell markers or gene mutations for activity.
Launch of Cytolytix
Speaking about the project, ValiRx CEO, Dr
As the major shareholder in Cytolytix, ValiRx will lead the development of CLX001 with oversight provided by the Cytolytix board, which comprises representatives from ValiRx, Kings College London, and
'This project is the first output of the strategy we launched in 2020 to bring new academic, early-stage projects into our pipeline and is an excellent example of the innovative science being carried out at
Contact:
Tel: +44 (0)2476 796496
Email: info@valirx.com
(C) 2022 Electronic News Publishing, source